ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced today that its common shares have been approved for listing on the American Stock Exchange (AMEX) and are expected to commence trading at the opening of the market on Tuesday, May 27, 2008. The Company is expected to trade on AMEX under the symbol “RNN”. This approval is contingent upon Rexahn being in compliance with all applicable listing standards on the date it begins trading on the AMEX and may be rescinded if Rexahn is not in compliance with such standards. Concurrent with its first trade on AMEX, Rexahn will no longer be quoted on the OTC Bulletin Board.
